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Cerebral white matter injury is a leading cause of adverse neurodevelopmental outcome in prematurely
born infants involving cognitive deficits in later life. Despite increasing knowledge about the pathophys-
iology of perinatal brain injury, therapeutic options are limited. In the adult demyelinating disease mul-
tiple sclerosis the sphingosine-1-phosphate (S1P) receptor modulating substance fingolimod (FTY720)
has beneficial effects. Herein, we evaluated the neuroprotective potential of FTY720 in a neonatal model
of oxygen-toxicity, which is associated with hypomyelination and impaired neuro-cognitive outcome.
A single dose of FTY720 (1 mg/kg) at the onset of neonatal hyperoxia (24 h 80% oxygen on postnatal day
6) resulted in improvement of neuro-cognitive development persisting into adulthood. This was associ-
ated with reduced microstructural white matter abnormalities 4 months after the insult. In search of the
underlying mechanisms potential non-classical (i.e. lymphocyte-independent) pathways were analysed
shortly after the insult, comprising modulation of oxidative stress and local inflammatory responses as
well as myelination, oligodendrocyte degeneration and maturation. Treatment with FTY720 reduced
hyperoxia-induced oxidative stress, microglia activation and associated pro-inflammatory cytokine
expression. In vivo and in vitro analyses further revealed that oxygen-induced hypomyelination is
restored to control levels, which was accompanied by reduced oligodendrocyte degeneration and
enhanced maturation. Furthermore, hyperoxia-induced elevation of S1P receptor 1 (S1P1) protein expres-
sion on in vitro cultured oligodendrocyte precursor cells was reduced by activated FTY720 and protection
from degeneration is abrogated after selective S1P1 blockade. Finally, FTY720s’ classical mode of action
(i.e. retention of immune cells within peripheral lymphoid organs) was analysed demonstrating that
FTY720 diminished circulating lymphocyte counts independent from hyperoxia. Cerebral immune cell
counts remained unchanged by hyperoxia and by FTY720 treatment.
Taken together, these results suggest that beneficial effects of FTY720 in neonatal oxygen-induced
brain injury may be rather attributed to its anti-oxidative and anti-inflammatory capacity acting in con-
cert with a direct protection of developing oligodendrocytes than to a modulation of peripheral lympho-
cyte trafficking. Thus, FTY720 might be a potential new therapeutic option for the treatment of neonatal
brain injury through reduction of white matter damage.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Preterm birth represents an international health problem
affecting up to 10% of newborns in the western world (Howson
et al., 2013). Major advances in neonatal intensive care have led
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infants (<1500 g). However, these patients are at risk to develop
cerebral white and grey matter injury making prematurity the
leading cause of neurodevelopmental disability in childhood
(Lindstrom et al., 2007; Volpe, 2009). Functional consequences
may involve permanent motor and cognitive deficits in later life
(Johnson et al., 2011; Wilson-Costello et al., 2005).
Cerebral oxygenation disturbances, like hypoxia–ischemia and
premature exposure to high oxygen levels are likely to contribute
to the pathogenesis of brain lesions. Aberrant responses to injury
may disrupt maturation of glial progenitors and neurons, which
fail to generate neuronal networks resulting in a specific preterm
brain phenotype (Back and Rosenberg, 2014; Ferriero, 2004). Based
on clinical observations (Collins et al., 2001), experimental work
confirmed the role of oxygen toxicity in preterm brain injury
(Felderhoff-Mueser et al., 2004; Sirinyan et al., 2006). Neonatal
hyperoxia-triggered neurodegeneration correlates with inflamma-
tory responses and induction of reactive oxygen species inducing
oligodendroglial cell death and hypomyelination associated with
ultrastructural changes of the developing white matter and
motor-cognitive deficits (Brehmer et al., 2012; Dzietko et al.,
2008; Gerstner et al., 2008; Pham et al., 2014; Ritter et al., 2013;
Schmitz et al., 2012, 2014; Sifringer et al., 2012, 2010, 2009;
Vottier et al., 2011).
Sphingosine-1-phosphate (S1P) is a phosphorylated sphin-
golipid regulating growth, survival, proliferation, and differentia-
tion of cells (Spiegel and Milstien, 2011). The S1P analogue and
receptor modulator fingolimod (FTY720) is approved for the treat-
ment of relapsing-remitting multiple sclerosis. Due its pleiotropic
effects, the detailed mechanisms of action are still unclear. Previ-
ous work suggests that degradation of S1P receptors by FTY720
leads to inhibition of immune cell migration from the peripheral
lymphoid organs into the circulation and thus into the CNS in clas-
sical neuro-immunological disorders such as experimental autoim-
mune encephalomyelitis (Aktas et al., 2010; Brunkhorst et al.,
2014). However, in addition to this classical role in lymphocyte
trafficking, FTY720 crosses the blood–brain barrier, gets activated
by sphingosine kinase 2 in the CNS and may directly modulate
CNS cells expressing S1P receptors, such as microglia and oligoden-
drocytes (Foster et al., 2007).
Beyond multiple sclerosis, several studies using adult neurode-
generative disease models, e.g. cerebral ischemia and Alzheimer’s
disease demonstrated a protective role of FTY720 (Brunkhorst
et al., 2014). Beneficial effects of FTY720 have been mainly linked
to immunomodulation and protection or trophic support of neu-
ronal cells. Additional cell-protective effects have been observed
in oligodendrocyte progenitor cell cultures. However, in vivo
effects of FTY720 on oligodendrocyte differentiation and associated
myelination are controversially discussed (Coelho et al., 2007; Jung
et al., 2007; Miron et al., 2008).
The present study was designed to investigate potential
neuroprotective effects of FTY720 in an in vivo model of preterm
brain injury (i.e. neonatal hyperoxia) and in primary pre-
oligodendrocyte cultures. The primary endpoint analysis was the
assessment of long-term, motor-cognitive development and
associated structural white matter alterations. To identify
the potential underlying mechanisms we further investigated
hyperoxia-mediated hypomyelination, oligodendrocyte degenera-
tion, and differentiation as well as oxidative stress and local
inflammation. A selective S1P receptor 1 antagonist was applied
on in vitro cultured pre-oligodendrocytes to verify specific interac-
tions between FTY720 and oligodendrocyte precursor cells. In
addition to these non-classical pathways FTY720s’ classical mode
of action involving alterations of leukocyte migratory pathways
were investigated.2. Materials and methods
2.1. Pharmaceutical compounds
FTY720 and biologically active, phosphorylated FTY720
(pFTY720) were kindly provided by Novartis Pharma (Switzerland).
FTY720 was dissolved in PBS and applied at 1 mg/kg. PBS served as
vehicle control. pFTY720 was reconstituted in dimethylsulfox-
ide/50 mM HCl as a 1 mM stock solution and was further diluted
in basal definedmedium (10–1000 nM), appropriate vehicle served
as control. The selective S1P receptor 1 antagonist W146 (Sigma–
Aldrich, Germany) was dissolved in 0.1% trifluoroacetic acid in
methanol according to the manufacturers’ instructions.2.2. Animals and experimental procedures
All animal experiments were approved and performed in
accordance with the guidelines of the University Hospital Essen,
Germany and with permission of the local animal welfare
committee.
Six-day-old Wistar rat pups were placed in an oxygen chamber
containing 80% oxygen (OxyCycler, BioSpherix, USA, 80% O2, 24 h;
HO) together with their lactating dams. Control pups were kept
under normoxic conditions (21% O2, NO). At the beginning of
hyperoxia animals received a single intraperitoneal injection of
1 mg/kg FTY720 or vehicle (four study groups: hyperoxia/PBS
(HO); hyperoxia/FTY720 (HO + FTY720); normoxia/PBS (NO); nor-
moxia/FTY720 (NO + FTY720). The dose of FTY720 was selected
according to previous reports in adult models of stroke (Czech
et al., 2009; Liesz et al., 2011). Bodyweight was recorded at P6,
P7, P9, P10, P11 and weekly after the weaning period. There were
no changes in weight gain between experimental groups. Pups
were sacrificed at P7, P11 and P125 under deep anaesthesia.
In accordance with our previous observations (Brehmer et al.,
2012; Felderhoff-Mueser et al., 2004) myelin basic protein (MBP)
expression and cellular degeneration were determined at P11
and P7, respectively. Functional deficits were analysed at P30 and
additionally at P90; and diffusion tensor imaging was carried out
at P125 to evaluate long term microstructural white matter and
behavioural abnormalities at the fully adult developmental stage
which has not been assessed in this specific model before. For
protein and mRNA analysis, rats were transcardially perfused with
PBS and brain hemispheres or dissected white matter fractions
(including corpus callosum, deep cortical white matter and
external capsule) were snap-frozen in liquid nitrogen. For
histological and MR imaging studies, pups were transcardially per-
fused with PBS followed by 4% paraformaldehyde (Sigma–Aldrich).
Brains were postfixed in 4% paraformaldehyde overnight at 4 C
and embedded in paraffin or sent for diffusion tensor imaging.
Based on previous experience (Brehmer et al., 2012) whole
hemispheres (excluding cerebellum) were used for Western blot
for overall evaluation of MBP expression. To correlate specific
effects on myelination with local inflammatory reactions and
oxidative stress induction we used dissected white matter
enriched preparations of single hemispheres for evaluation of
ionised calcium binding adapter molecule 1 (Iba1) protein expres-
sion, IL-1b and TNFa protein and mRNA expression and for analysis
of oxidative stress related parameters. For lymphocyte cell count
analysis via flow cytometry, whole brains (excluding cerebellum)
had to be used due to very few immune cells which can be isolated
from individual brains.
A total of 285 (138 female and 147 male) rat pups were enrolled
in the study and randomly assigned to the treatment groups. Gender
distribution is depicted as female/male (f/m) in the following
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for behavioural testing. Out of these brains of 6 animals (3/3) of
each experimental group were subjected to diffusion tensor
imaging. A second cohort was used for western blot and
immunohistochemistry analysis of MBP expression (NO: n = 10
(5/5), NO + FTY720: n = 10 (6/4), HO: n = 11 (4/7), HO + FTY720:
n = 12 (5/7)) and (NO: n = 10 (6/4), NO + FTY720: n = 10 (6/4),
HO: n = 12 (6/6), HO + FTY720: n = 12 (5/7)) respectively. A third
set was used to assess oxidative stress parameters (NO: n = 8
(5/3), NO + FTY720: n = 9 (4/5), HO: n = 9 (5/4), HO + FTY720:
n = 9 (4/5)). For Western blot analysis of Iba1, IL-1b and TNFa pro-
tein and mRNA expression another cohort was generated (NO:
n = 10 (4/6), NO + FTY720: n = 10 (5/5), HO: n = 12 (6/6), HO
+ FTY720: n = 10 (5/5)). These animals were also used for
quantification of pro-inflammatory plasma cytokine levels. For
immunohistochemical detection of oligodendrocyte degeneration/
maturation and microglia activation a fifth set was evaluated
(NO: n = 10 (4/6), NO + FTY720: n = 10 (4/6), HO: n = 12 (6/6), HO
+ FTY720: n = 10 (5/5)). Another set of animals was used for flow
cytometry analysis of blood and brain (NO: n = 11 (6/5), NO
+ FTY720: n = 11 (5/6), HO: n = 10 (4/6), HO + FTY720: n = 11 (6/5)).2.3. Immunoblotting
Western blotting was performed as described previously
(Brehmer et al., 2012), with adaptions in epitope detection. Mem-
branes were incubated overnight (4 C) with a primary monoclonal
mouse anti-MBP antibody (1:10,000, Abcam, UK), detecting two
classical isoforms at 18.5 kDa and 21.5 kDa. The 21.5 kDa isoform,
known to be increased during active early myelination (Harauz
and Boggs, 2013) was quantified. Further epitopes were detected
by polyclonal rabbit anti-Iba1 antibody (17 kDa, 1:1000, Wako,
Japan), polyclonal rabbit anti-rat IL-1b (17 kDa; 1:500), polyclonal
rabbit anti-rat TNFa (17 kDa; 1:500, both from PromoKine,
Germany), polyclonal rabbit anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antibody (37 kDa; 1:1000, Santa Cruz,
Germany) or monoclonal mouse anti-b-actin antibody (42 kDa;
1:500; Sigma–Aldrich). Antibodies were diluted in 5% non-fat dry
milk in Tris buffered saline, 0.05% Tween-20 (TBST, Sigma–Aldrich).
Horseradish peroxidase-conjugated secondary anti-mouse or anti-
rabbit antibody (1:5000 Dako, Denmark) was diluted in 5% non-fat
drymilk in TBST. Antibody bindingwas detected by using enhanced
chemiluminescence (GE healthcare Life Sciences, Germany). For
visualisation and densitometric analysis ChemiDoc XRS+ imaging
system and ImageLab software (Bio-Rad, Germany) were used.2.4. Immunohistochemistry and confocal microscopy
After deparaffinization, 10 lm coronal sections
(3.72 ± 0.7 mm from bregma) were rehydrated. Antigen-
retrieval was performed in a pre-heated 10 mM sodium-citrate
buffer (pH 6.0) for 30 min. After blocking with 1% bovine serum
albumin, 0.3% cold fish skin gelatine in 0.1% Tween-20 TBS (all
Sigma–Aldrich) slides were incubated with primary antibodies
overnight at 4 C followed by appropriate secondary antibody
incubation for 1 h at room temperature. Sections were counter-
stained with 40,6-diamidino-2-phenylindole (DAPI) (1 lg/ml, Invit-
rogen, Germany).
Myelination was evaluated at P11 using the primary mouse
anti-rat MBP antibody (1:100, SMI-99, Sternberger Monoclonals,
USA). Microglia activation was detected by Iba1 (1:1000, rabbit
polyclonal anti-Iba1, Wako) staining on section of P7 old rats.
Degeneration of oligodendrocytes or neurons were evaluated at
P7 via co-labelling with Olig2 (1:100, polyclonal rabbitanti-Olig2, Millipore, Germany) or NeuN (1:200, polyclonal rabbit
anti-NeuN, Millipore) and terminal deoxynucleotidyltransferase-
mediated biotinylated dUTP nick end labelling (TUNEL, In Situ cell
death detection kit, FITC; Roche, Germany), performed according to
the manufacturers’ instructions. Mature oligodendrocytes were
identified by adenomatous polyposis coli, clone CC1 (referred as
CC1; 1:100, monoclonal mouse anti-APC, Calbiochem, Germany)
and Olig2 (1:100; polyclonal rabbit anti-Olig2, Millipore)
co-stainings. All primary antibodies were followed by appropriate
secondary antibody staining (anti-rabbit Alexa Fluor 594 (1:300),
anti-mouse Alexa Fluor 488 (1:500); Invitrogen).
Stained brain sections were analysed by confocal microscopy
(A1plus, Eclipse Ti, with NIS Elements AR software, Nikon,
Germany) using 10 or 20 objectives. Two laser lines
(laser diode, 405 nm; Ar laser, 514 nm; G-HeNe laser, 543 nm)
and three different filters (450/50-405 LP, 515/20-540 LP,
585/65-640 LP) were used for image acquisition. Confocal
z-stacks of 10 lm thickness (z-plane distance 1 lm) were
converted into 2-dimensional images using maximum intensity
projections. Image acquisition and analysis were performed by
an observer blinded to treatment. The quantification of each stain-
ing was performed with the NIS Elements AR software. For MBP
stained sections, large scale images (stitching) of complete hemi-
spheres from two sections per animal were acquired followed by
measurement of mean pixel intensities. Morphometric changes of
microglia (Iba1), were determined in a total of 12 images (each
396,900 lm2) derived from 2 sections per animal within 3 regions
of interest (ROI) in the white matter (cingulate, deep cortical,
external capsule). The circularity of Iba1 positive cells was mea-
sured on single demarcated cells. A total of 2897 cells (n = 715
NO, n = 681 NO + FTY720, n = 771 HO, n = 730 HO + FTY720) was
analysed. Degenerating oligodendrocytes or neurons and maturat-
ing oligodendrocytes were analysed by counting triple positive
cells in 6 ROIs derived from 2 sections per animal (each ROI:
396,900 lm2, cortex, deep cortical white matter, thalamus).
2.5. Real-time PCR
Gene expression analysis was performed as previously
described using the PCR ABI Prism 7500 (Brehmer et al., 2012).
The PCR products of IL-1b (NM_031512), TNFa (NM_012675), S1P
receptor 1 (Rn02758712_s1; life technologies, Germany), S1P recep-
tor 3 (Rn02758880_s1; life technologies, Germany), S1P receptor 5
(Rn00572952_s1; life technologies, Germany) and b-actin (as inter-
nal standard, NM_031144) were quantified by fluorogenic reporter
oligonucleotide probes (Sifringer et al., 2013). Real-time PCR and
detection were performed in triplicate, measurements were
repeated 3 times for each sample. Target gene expression was
quantified according to the 2DDCT method.
2.6. Evaluation of oxidative stress parameters
Oxidative stress response was measured in white matter homo-
genates. Total glutathione (GSH and GSSH) was assessed by using
the thiol reagent 5,50-dithiobis-2-nitrobenzoic acid (DTNB) and 4-
vinylpyridine, and lipid peroxidation was determined by the reac-
tion of thiobarbituric acid with malondialdehyde (MDA) as previ-
ously described (Sifringer et al., 2010).
2.7. Behavioural studies
Behavioural testing was initiated in adolescent animals on post-
natal day 30 (P30) and repeated on P90 in adult animals. From P20
on animals were familiarised with the investigator through
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inversed 12 h light–dark cycle. Testing was started with 1 day of
open field followed by 4 days of Barnes maze. Data were recorded
using an automatic tracking system (Video-Mot2, TSE Systems,
Germany) and exported for statistical analysis.
For the open field test (DeFries et al., 1966), animals were
placed into the centre of a dimly lit open field arena
(50  50  40 cm, or 75  75  40 cm for adult animals), placed
upon an infrared-box (850 nm, TSE Systems). Movements were
recorded by the tracking system for 5 min. Activity and anxiety,
i.e. travelled distance, velocity and the percentage of time the ani-
mal stayed in the central area of the box in relation to the total
time spent in the arena were analysed. For Barnes maze (Barnes,
1979) animals were placed into the centre of the maze (1.22 m
width, 0.8 m height, 20 holes at the border, TSE Systems) under
red light followed by bright light to allow the animal to recognise
extra-maze cues. The animal was allowed to explore the maze and
find the escape box within 120 s, animals were left in the escape
box for 1 min. Animals who did not find the escape box were
gently placed into the escape box for 1 min. To avoid intra-maze
cues due to odour the escape box was clockwise rotated for every
other animal, with the same escape location for each animal at the
three training days. The latency to find the trained escape box was
assessed on the fourth day of each experiment when all holes were
closed (O’Leary et al., 2011).
2.8. Diffusion tensor imaging
At P125, ex vivo brains from the behaviour tested animals were
subjected to diffusion tensor MR imaging. All experiments were
performed on an actively-shielded 9.4T/31 cm magnet (Varian/
Magnex Scientific, UK) equipped with 12 cm gradient coils
(400 mT/m, 120 ls) with a transceiver 25 mm birdcage volume
RF coil. First and second order shims were adjusted manually; with
a water bandwidth ranged between 20 and 30 Hz. Diffusion gradi-
ents were applied along six spatial directions in a spin echo
sequence (Basser and Pierpaoli, 1998). The intensity (Gd), duration
(d) and separation time of the pulsed diffusion gradients were set
to 22 G/cm, 3 ms and 20 ms, respectively (b-value of 1185
s/mm2). A field of view of 27  27 mm2 was sampled on a
128  128 cartesian grid and 12 slices of 0.8 mm thickness were
acquired in the axial plane with 20 averages. The echo time was
set to 35 ms and the repetition time between consecutive mea-
surements was 2000 ms. Using homemade Matlab (Mathworks,
MA) software, the radial diffusivity (D\), the axial diffusivity
(D//), the mean diffusivity (MD) and the fractional anisotropy (FA)
were derived from the tensor. The program allows manual delin-
eation of region of interest (ROI) on the direction encoded colour
maps. On three different structures of the brain (cortex (Cx), corpus
callosum (CC) and external capsule (EC)), ROIs were carefully man-
ually delimited at six different image-planes of the brain from the
genu to the splenium of the corpus callosum.
2.9. Primary oligodendrocyte cultures and immunocytochemistry
Primary oligodendrocytes were isolated from brains of Sprague
Dawley rats at P1–P2 as previously described (Brehmer et al.,
2012). After 3 to 5 days (O4-maturity level), activated FTY720
(pFTY720) was added at different concentrations (10–1000 nM)
at the onset of hyperoxic (80% oxygen, CB 150 incubator, Binder,
Germany) or standard culture conditions for 24 h. The selected
concentration range for studying in vitro effects of pFTY720 treat-
ment was based on previous reports in rat oligodendrocyte precur-
sor cells (Coelho et al., 2007; Jung et al., 2007).
Immunocytochemical analysis was conducted to determine S1P
receptor 1 (S1P1) protein expression on pre-oligodendrocytes.Briefly, cells were blocked with 5% normal goat serum in 0.1%
Triton X-100 (Sigma–Aldrich) in PBS for 1 h at room temperature
followed by incubation with anti-S1P1 (polyclonal rabbit
anti-Edg1, 1:300, abcam) and anti-Olig2 (monoclonal mouse
anti-Olig2, 1:500, Millipore) at 4 C overnight. Antibody binding
was visualised by incubation with the appropriate secondary
antibodies (1:1000 anti-rabbit Alexa Fluor 488, 1:1000
anti-mouse Alexa Fluor 594; both Invitrogen). Per group and
experiment 5–6 random fields (each 45,500 lm2) were visualised
by fluorescence microscopy (Axioplan; Zeiss, Germany) connected
to a CCD camera (Microfire; AVT Horn, Germany). The mean signal
intensity of S1P1 was measured on single Olig-2 positive cells
using Image J. A total of 1437 cells (NO n = 380, NO+: n = 411,
HO: n = 375, HO+: n = 271) were analysed while being blinded to
the experimental groups.
The differentiation capacity of premature oligodendrocytes in
response to a single dose of activated FTY720 was evaluated in iso-
lated premature oligodendrocytes that were treated with pFTY720
or vehicle and cultured as above. Cells were further cultivated
under differentiating conditions (basal defined medium
supplemented with 10 ng/ml triiodothyronine (Sigma–Aldrich)
and 10 ng/ml ciliary neurotrophic growth factor (Pan-Biotech,
Germany) for another 3 days in the absence of FTY720. MBP
expression of oligodendrocytes was evaluated by MBP/Olig2
co-staining. After fixation cells were blocked with 5% normal goat
serum in 0.1% Triton X-100 (Sigma–Aldrich) in PBS and incubated
overnight with anti-rat MBP (1:500, SMI-99, Monoclonals, USA)
and anti-Olig2 (monoclonal mouse anti-Olig2, 1:500, Millipore)
at 4 C, followed by secondary antibody (1:1000 anti-mouse, Alexa
Fluor 488; 1:1000 anti-rabbit, Alexa Fluor 594) incubation for 1 h
at room temperature. Immature oligodendrocytes were stained
for O4 (1:750, MO15002, Neuromics, USA) and Olig2 (1:200)
overnight at 4 C and incubated with appropriate secondary
antibodies (1:1000 anti-mouse Alexa Fluor 488; 1:1000
anti-rabbit Alexa Fluor 594, Invitrogen) for 1 h at room tempera-
ture. Nuclei were counterstained with DAPI (100 ng/ml). Five
random fields (each 189,140 lm2) were visualised by fluorescence
microscopy and triple-positive cells were counted for each
condition.
To specifically block the S1P receptor 1 premature oligodendro-
cytes were incubated with 10 lM of a selective pharmacological
S1P receptor 1 receptor antagonist (W146) or vehicle for 30 min
prior to the start of hyperoxia/normoxia and addition of 50 nM
pFTY720. The W146 dose was chosen based on previous reports
demonstrating efficient blockade of protection by pFTY720 in a
model of excitotoxicity (Di Menna et al., 2013).
2.10. Processing of peripheral blood and brain tissues
Isolation of single cell suspension for flow cytometry analysis
was performed as previously described (Herz et al., 2014). Briefly,
animals were euthanised by i.p. injections of chloralhydrate. Blood
specimens were collected into ethylenediaminetetraacetate
(EDTA) coated collection tubes by puncture of the inferior vena
cava followed by transcardial perfusion with ice-cold PBS and
removal of brains. Erythrocytes were lysed by incubation with lysis
buffer (155 mM NH4Cl, 10 mM KHCO3, 3 mM EDTA) for 5 min fol-
lowed by two washing steps with PBS prior to staining. Brains were
dissected, cerebellum removed followed by homogenisation
through a 40 lm cell strainer (BD Biosciences, Germany) during
continuous rinsing with 15 mL of cold HEPES-buffered RPMI1640.
Samples were centrifuged at 400g for 5 min at 18 C. The super-
natants were discarded and the pellets were re-suspended in 37%
Percoll in 0.01 N HCl/PBS and centrifuged at 2800g for 20 min.
Myelin was removed and the remaining cell pellet was washed
twice in PBS.
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Fig. 1. FTY720 improves memory function and white matter microstructure
development in adult rats after neonatal hyperoxia-mediated brain injury. (A and
B) Cognitive development was assessed in the Barnes maze test starting at P31 and
P91 after exposure to 24 h normoxia (21% O2; (NO)) or hyperoxia (24 h 80% O2;
(HO)) at P6 and treated with PBS or 1 mg/kg FTY720. Memory function is expressed
as the latency to find the trained escape hole after a 3-day-training period. n = 8–
10 rats/group. (C) Representative direction-encoded colour maps of a P125 NO rat
derived from diffusion tensor imaging showing the different levels used for
quantitative analysis. ROIs: corpus callosum (CC), external capsule (EC) and cortex
(CX) are displayed on the maps. (D and E) Quantification of fractional anisotropy in
corpus callosum and external capsule determined by diffusion tensor imaging.
n = 6 rats/group. *p < 0.05, **p < 0.01.
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Isolated cells were incubated with the following antibodies:
anti-CD45 PE-Cy7 (leukocytes, clone OX-1, BD Biosciences), anti-CD3
APC (T cells, clone: REA223, Miltenyi Biotec, Germany), anti-CD161a
Fitc (NK cells, clone 10/78, BD Biosciences) and anti-CD45RA
APC-Cy7 (B cells, clone: OX-33, BD Biosciences) for 30min at 4 C
followed by two washing steps prior to analysis Total cell counts of
blood- and brain-derived leukocytes were determined using BD
TrueCount beads on the basis of CD45 positive events.
Isolated oligodendrocytes were harvested by trypsinization
(0.05% Trypsin–EDTA, Gibco, Germany) for 2-3 min. A2B5-
positive oligodendrocytes (biotinylated anti-A2B5, 1:50, Miltenyi
Biotec; followed streptavidin-coupled Alexa Fluor 488, 1:1000;
Invitrogen) were co-labelled with the PE Apoptosis Detection Kit
(BD Biosciences) according to the manufactures’ instructions. Data
acquisition and analysis were performed were using the BD FACS
LSRII and FACS Diva software (BD Biosciences).
2.12. Analysis of plasma cytokines
Blood from the vena cava was collected in ethylenediaminete-
traacetate (EDTA) coated tubes. Samples were centrifuged at
1000g for 10 min and the supernatant was frozen at 80 C until
further analysis. Plasma samples were assayed for the presence of
IL-1a, IL-1b, TNFa and IFNc using a Luminex Screening assay (R&D
Systems, Germany) according to the manufacturers’ instructions.
Samples were analysed by Luminex 200 technology using Luminex
IS software (Luminex Corporation, USA).
2.13. Statistical analysis
Data are presented as mean ± standard deviation (SD) with
Prism 6 (GraphPad Software, USA). Statistical analyses were
performed with SPSS 22 (IBM, USA), differences between groups
were determined by two-way analysis of variance (two-way
ANOVA) followed by Bonferroni post hoc test for multiple compar-
ison. For MRI results, nonparametric Mann–Whitney test was used.
p-values less than 0.05 were considered as statistically significant.3. Results
3.1. FTY720 improves long-term cognitive development and reduces
white matter injury after neonatal hyperoxia
To assess the effect of FTY720 treatment on motor activity and
cognitive function after neonatal (P6) exposure to hyperoxia (24 h
80% oxygen (HO), (Brehmer et al., 2012; Schmitz et al., 2014), we
performed behavioural tests in adolescent (P30) and adult (P90)
rats. General motor activity assessed in the open field was not
affected by hyperoxia or FTY720 treatment (Supplemental
Fig. S1). However, spatio-temporal learning evaluated in the Barnes
maze was significantly decreased after neonatal hyperoxia
persisting into adulthood (P90) (Fig. 1A and B). Interestingly,
FTY720 treatment improved hyperoxia-induced memory deficits
as shown by decreased latency to control levels at P30 and P90
(Fig. 1A and B). To determine whether these functional deficits
were associated with white matter structure development diffu-
sion tensor imaging (DTI) was performed on brains of P125 old rats
(Fig. 1C–E, Supplemental Fig. S2). Fractional anisotropy (FA) mea-
sured in the corpus callosum and the external capsule was signif-
icantly reduced in the HO group compared to normoxic controls
(Fig. 1D and E). Mostly, this FA decrease was related to a significant
increase of radial diffusivity (D\) in the white matter of HO rats
(Supplemental Fig. S2). Of note, single FTY720 treatmentameliorates neonatal hyperoxia-induced white matter injury
demonstrated by a sustained increase of FA values in the hyperoxic
brain (Fig. 1D and E). In the cortex, no significant differences were
observed between the analysed groups (data not shown).
3.2. Hyperoxia-mediated hypomyelination in the developing brain is
ameliorated by FTY720 treatment
Cognitive deficits have been associated with white matter
changes in preterm born children (Soria-Pastor et al., 2008), and
are supposed to be related to several adult neurological diseases
(Nave and Ehrenreich, 2014). Therefore, we investigated the
myelination capacity of developing oligodendrocytes after
exposure to hyperoxia by MBP protein expression at P11 via
immunohistochemistry and Western blotting. A significant
decrease of MBP protein expression was detected in hyperoxia-
exposed animals as compared to normoxic controls (Fig. 2).
Hyperoxia-induced hypomyelination was partially reversed by
FTY720 treatment leading to significantly increased levels of MBP
expression for the combined treatment of FTY720 and hyperoxia
when compared to hyperoxia only (Fig. 2B and C).
3.3. FTY720 ameliorates hyperoxia-triggered oxidative stress response
in the developing white matter
In search of underlying mechanisms for the observed protective
effects to hypomyelination by FTY720 treatment we evaluated the
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hyperoxia-mediated neonatal brain injury (Schmitz et al., 2014;
Sifringer et al., 2010). The measurement of reduced and oxidised
glutathione revealed a decrease in reduced and an increase in
oxidised glutathione in hyperoxic rats (Fig. 3A–C). However, these
hyperoxia-triggered imbalances were neither detectable in control
nor in FTY720 treatment animals (Fig. 3A–C). Furthermore, by
measurement of malondialdehyde (MDA), a marker for lipid
peroxidation, we detected an increase in MDA concentration in(A)
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Fig. 3. Augmented hyperoxia-triggered oxidative stress response in the developing
white matter is prevented by FTY720 treatment. White matter fractions of P7 rats
exposed to 24 h NO or HO combined with PBS or FTY720 treatment at P6 were used
for measurement of the oxidative stress response. (A–C) Reduced (GSH) and
oxidised glutathione (GSSH) levels was measured by spectrophotometric analysis at
412 nm. (D) Lipid peroxidation was determined by HPLC measurement of malon-
dialdehyde (MDA). n = 8–9 rats/group. ***p < 0.001.the white matter of hyperoxic rats, which is significantly reduced
upon FTY720 treatment (Fig. 3D).
3.4. Hyperoxia-induced local inflammatory response and microglia
activation is prevented by FTY720 treatment
Since an increase in oxidative stress response after neonatal
hyperoxia coincides with induction of inflammatory cytokines
and microglia activation (Schmitz et al., 2014; Sifringer et al.,
2010) we analysed FTY720’s potential immunomodulatory effect.
We detected an eightfold increase in IL-1b mRNA and a tenfold
increase in TNFa mRNA expression in the hyperoxic white matter
whereas in FTY720 treated animals expression decreased almost
comparable to control levels (Fig. 4A and C). To corroborate these
findings on the protein level we performed Western blot analyses
confirming significant regulations on the transcriptional level
(Fig. 4B and D). Immunohistochemical analysis of microglia activa-
tion revealed a shift of Iba1-positive cells from a resting, ramified
to a more activated, amoeboid microglia phenotype in hyperoxic
samples, not observed in FTY720-treated hyperoxic rats (Fig. 4E).
By assessing the total amount of Iba1 positive cells we did not
observe marked alterations in total microglia numbers (Fig. 4F),
however, microglia circularity was increased in the hyperoxic
group which was undetectable in the other groups (Fig. 4G).
Furthermore, using Western blot analysis we observed an increase
in Iba1 protein expression after hyperoxia, which is ameliorated by
FTY720 administration (Fig. 4H). These results combined with
morphological changes suggest a more activated microglia
phenotype in response to hyperoxia that is decreased by FTY720.
3.5. FTY720 induces reduced circulating lymphocyte cell counts
independent of hyperoxia
Considering FTY720s’ classical immunomodulatory role associ-
ated with retention of lymphocytes in peripheral lymphoid organs
resulting in reduced circulating and brain-infiltrating numbers in
autoimmune mediated neuroinflammation (Fujino et al., 2003;
Kataoka et al., 2005) we performed flow cytometry on different
lymphocyte subsets in the blood and brain differentiated by their
antigen expression using multichannel flow cytometry. Absolute
cell counts of circulating leukocytes were reduced by FTY720
both under normoxic and under hyperoxic conditions (Fig. 5A).
FTY720-induced reduction of circulating white blood cells can be
mainly attributed to a reduced number of lymphocytes particularly
T and B cells (Fig. 5A). These results might support the concept that
FTY720 restrains lymphocytes within the lymphoid organs result-
ing in reduced circulating lymphocyte counts. In spite of reduced
peripheral lymphocyte counts after FTY720 administration, which
was independent of hyperoxia, there were no significant changes
in the level of circulating cytokines, i.e. IL-1b, IL-1a, TNFa,
IFNc (Supplemental Fig. S3). Of note, brain lymphocyte
counts were modulated neither by FTY720 nor by hyperoxia
(Fig. 5B). Taken together, these data suggest that peripheral
immunmodulatory effects of FTY720 are independent of FTY720s’
local anti-inflammatory and anti-oxidative capacity in the
hyperoxic brain and might therefore not explain the neuroprotective
effect in the present model.
3.6. Hyperoxia-induced oligodendrocyte degeneration and impaired
maturation is attenuated by FTY720
To get deeper insight into the underlying causes of FTY720s’
protective effect on hyperoxia-induced hypomyelination and
cognitive deficits we investigated oligodendrocyte degeneration
and maturation by performing TUNEL and CC1 staining in
combination with the pan-oligodendrocyte marker Olig2. We
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Fig. 4. Hyperoxia-associated inflammatory response and microglia activation in the developing white matter is prevented by FTY720. Local inflammatory response assessed
by IL-1b and TNFamRNA (A and C) and protein (B and D) expression in isolated white matter fractions of P7 rats exposed to 24 h room-air (NO) or hyperoxia (HO) combined
with PBS or FTY720 treatment, n = 10–12 rats/group. (E) Representative images of immunohistochemical staining of activated microglia (Iba1) in the cingulate white
matter (scale bar = 100 lm). (F and G) Quantification of microglia cell number and circularity. (H) Protein expression analysis of Iba1 in isolated white matter fractions.
n = 10–12 rats/group. *p < 0.05, **p < 0.01, ***p < 0.001.
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developing white matter after 24 h of hyperoxia, which was
abolished in FTY720 treated animals (Fig. 6A and B). Neither hyper-
oxia nor FTY720 treatment affected neuronal degeneration in the
white matter (WM) and hippocampus (HC) (WM: NeuN/TUNEL+
cells/mm2: NO = 1.11 + 0.69, NO + FTY720 = 0.92 + 0.92, HO = 1.33
+ 0.78, HO + FTY720 = 1.17 + 0.64 cell/mm2, p = 0.89 and HC:
NeuN/TUNEL+ cells/mm2, NO: 5.39 + 1.37, NO + FTY720: 4.82 + 0.71,
HO: 5.5 + 1.45, HO + FTY720: 5.79 + 1.30; p = 0.35). Oligodendrocytes
(Olig2) co-labelled with CC1, a marker for mature oligodendrocytes
showed a significant drop of CC1 positive oligodendrocytes in the
developing white matter in rats exposed to hyperoxia, which
was counterbalanced by FTY720 treatment (Fig. 6C and D). Similar
effects of oligodendrocyte degeneration and impaired maturation
were observed in the thalamus and cortex (Supplemental
Fig. S4A–D) whereas the amount of degenerating oligodendrocytes
in the hippocampus remained unchanged (Olig2/TUNEL+ cells/mm2,
NO: 2.41 + 0.72, NO + FTY720: 2.66 + 0.52, HO: 2.33 + 0.73, HO
+ FTY720: 2.46 + 0.48, p = 0.68).3.7. pFTY720 reduces hyperoxia-induced cell death and improves
differentiation of primary oligodendrocytes
To test whether FTY720-induced hypomyelination is a
consequence of reduced oxidative stress and local inflammation
or whether FTY720 might also directly target immature oligoden-
drocytes we used a primary immature oligodendrocyte culture
model. Immature oligodendrocytes (O4-maturity level) were cul-
tured in the presence or absence of biological active FTY720
(pFTY720). pFTY720 does not affect morphology or number of cells
under standard culture conditions (NO). However, hyperoxia
markedly decreased the total amount of oligodendrocytes and
their processes in the absence of pFTY720 whereas the number
of primary O4 positive oligodendrocytes and their processes are
increased in the presence of FTY720 (Fig. 7A). We confirmed this
protective effect on cell degeneration by flow cytometry demon-
strating that hyperoxia leads to a shift from vital to apoptotic cells
(0 nM, NO vs. HO) which decreases upon pFTY720 treatment
(Fig. 7B). Quantification of three independent experiments
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totic cells by hyperoxia which is partially reversed by pFTY720
treatment (Fig. 7C and D). In addition to enhanced oligodendrocyte
survival pFTY720 restores oligodendrocyte differentiation as
demonstrated by an increased MBP expression and a higher number
of differentiated oligodendrocytes in pFTY720-treated hyperoxic
oligodendrocytes. Quantification of myelinating oligodendrocytes
revealed no significant differences under normoxic culture
conditions for all pFTY720 concentrations, tested (Fig. 7E–G).
3.8. Cellular protection by activated FTY720 is abrogated following
pharmacological S1P receptor 1 blockade
To get deeper insights into pFTY720s’ mode of action on oligo-
dendrocyte precursor cells we determined mRNA expression levels
of S1P receptors, namely S1P1, S1P3 and S1P5 on in vitro cultured
pre-oligodendrocytes. In agreement with previous reports (Miron
et al., 2008) basal S1P1 expression on oligodendrocyte precursor)
/
)cells was increased compared to S1P5 and S1P3 expression under
normoxia (Fig. 8A). We further focused on the modulation of
S1P1 by hyperoxia and 50 nM pFTY720 since this concentration
was efficient to protect pre-oligodendrocytes from hyperoxia-
induced apoptosis and differentiation arrest (Fig. 7C and D). Hyper-
oxia increases S1P1 expression on protein and mRNA level
(Fig. 8B). Whereas pFTY720 did not alter S1P1 mRNA we detected
significantly decreased S1P1 protein expression at the single cell
level (Fig. 8C and D). To verify the functional relevance we specif-
ically inhibited the S1P1 prior to hyperoxia and pFTY720 treatment
demonstrating that pFTY720s’ cell protective effect was dimin-
ished through this selective pharmacological blockade (Fig. 8E).4. Discussion
The present study demonstrates that FTY720 modulates the
hyperoxia-exposed neonatal brains’ microenvironment through
reduction of inflammation and oxidative stress accompanied by a
direct action on oligodendrocyte precursor cell development
resulting in long-term improvement of white matter structures
and cognitive function in later life.
Cerebral grey and white matter injury are the leading cause of
motor and cognitive impairment in later life of preterm infants
(Volpe, 2009). Inflammation and disturbed oxygenation have been
identified as major causes for acute and chronic white matter
injury (Back and Rosenberg, 2014). Myelination is the key to the
functional activity of axons, allowing them to connect to neurons
and strengthen circuitry throughout the nervous system not only
during development but also in the adult CNS (de Hoz and
Simons, 2015). Clinical studies revealed that cognitive and motor
deficits in preterm born infants can be directly related to
microstructural abnormalities in particular white matter regions
(Counsell et al., 2008). In contrast to human brain development,
there is a delay in rodent brain maturation, i.e. oligodendrogenesis
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to preterm born human infants (23–36 weeks of gestation)
(Semple et al., 2013). Previous experimental studies revealed that
neonatal hyperoxia-triggered neural cell degeneration leads to a
transient hypomyelination with long-lasting microstructural
changes in the white matter (Brehmer et al., 2012; Dzietko et al.,
2008; Felderhoff-Mueser et al., 2004; Schmitz et al., 2014;
Sifringer et al., 2012). We observed similar changes in white matter
microstructures on diffusion tensor imaging scans, i.e. reduced
fractional anisotropy and increased diffusivity of adult rat brains
following neonatal hyperoxia that is restored by a single FTY720
treatment. The present study shows that FTY720 significantly
increases MBP expression in the developing rat brain following
neonatal hyperoxia. Impaired myelination is associated
with significant cognitive deficits of hyperoxic rats in later
life. These data support a recent report showing that disrupted
axon-oligodendrocyte integrity in a hyperoxic model of premature
brain injury results in long-lasting impairment of conduction
properties in the adult white matter (Ritter et al., 2013). Of note,
hyperoxia-mediated hypomyelination is a transient phenomenon,
since significant changes in MBP expression that become evident
at P10–P11 are normalised to control levels 9–15 days following
hyperoxia exposure. Moreover, hyperoxia-induced apoptosis and
loss of CC1+ cells occur immediately after hyperoxia (P7) and last
for maximal 48 h (Brehmer et al., 2012; Felderhoff-Mueser et al.,2004; Schmitz et al., 2014). However, these transient effects
directly translate into long-term alterations of white matter brain
structures, which can be detected as early as at P21 and persist
up to P60 (Brehmer et al., 2012; Schmitz et al., 2014). Considering
the brains plasticity in this developmental stage and the fact that
axons continue to myelinate into the second and third decade
one limitation of previous pre-clinical studies is the lack of data
from P60 onwards which can provide insight into maturation of
white matter structures throughout adulthood (Semple et al.,
2013). Therefore, we included analyses of functional deficits and
microstructural white matter abnormalities at the fully adult
developmental stage (>P90) demonstrating that FTY720-mediated
acute neuroprotection by prevention of oligodendrocyte degeneration
and maturation arrest results in long-term protection. These
findings emphasise the need of acute therapies during the very vul-
nerable phase of brain maturation to enhance the developmental
and regenerative potential of the preterm brain. Since premature
infants are exposed to partial oxygen concentrations that are
fourfold higher compared to intrauterine conditions, any therapy
can be applied immediately at onset of hyperoxia/birth. The present
study was carried out as a first proof-of-principal analysis to inves-
tigate FTY720s’ effects on acute brain injury and corresponding
long-term developmental processes. Nevertheless, further studies
applying delayed treatment paradigms might uncover additional
target mechanisms promoting regenerative capacities in response
to neonatal brain injury.
Recent work in models of cerebral ischemia and Alzheimer’s
disease have demonstrated that FTY720 improves neurological
outcome in adult rodents (Brunkhorst et al., 2014). However, aeti-
ology, underlying pathology and timing of the insult significantly
differ from the pathogenesis of neonatal white matter damage,
and functional outcome measures largely concentrated on motor
function as direct consequences of injury (e.g. d3–d15 post injury).
Our study focused on long-term analysis of cognitive capacities up
to 3 months following the insult. Only sparse data exists on
long-term cognitive function after FTY720 treatment which
mainly focuses on adult hippocampal learning and memory.
Intra-hippocampal injection of Ab1–42 followed by 14 days of
FTY720 treatment ameliorated spatial learning in Morris water
maze at the end of treatment (Asle-Rousta et al., 2013). Whereas
these effects were attributed to reduced hippocampal damage,
we do not find cell degeneration to a large extend in our model.
Therefore, the development of neuronal networks through
restoration of disturbed myelination rather than inhibition of
direct neurodegeneration in the hippocampus might be the
underlying mechanism explaining the present observations.
Proposed lymphocyte-independent mechanisms of FTY720
include reduced brain inflammation and nitrosative stress and
direct neuroprotective effects (Brunkhorst et al., 2014). Although
we detected the suggested reduction of circulating lymphocyte
counts after FTY720 treatment, this effect was independent of
hyperoxia. Therefore, we hypothesise that the beneficial effects
of FTY720 in neonatal oxygen-induced brain injury may be rather
attributed to inhibition of microglia activation than to modulation
of lymphocyte trafficking between peripheral lymphoid organs, the
circulation and the CNS. This is further supported by the fact, that
the relative mild neonatal hyperoxia model (24 h) used in the pre-
sent study does not involve increased infiltration of peripheral
immune cells to brain. However, hyperoxia is strongly associated
with an increased level of microglia activation. A microglial
response to FTY720 has been postulated in a model of adult
cerebral ischemia and excitotoxicity showing that it decreases total
microglia counts (Cipriani et al., 2015; Czech et al., 2009).
However, in brain slices microglial numbers were increased by
FTY720 treatment whereas their activation status remains
unchanged (Miron et al., 2010). In vivo effects of FTY720 on
116 M. Serdar et al. / Brain, Behavior, and Immunity 52 (2016) 106–119activation and effector mechanisms of microglia have been rarely
addressed. Instead, in vitro studies revealed reduction of pro-
inflammatory cytokine production including TNFa and IL-1b
(Noda et al., 2013). We did not observe a modulation of total
microglia cell counts but a reduced level of microglia activation
suggesting reduced IL-1b and TNFa production after FTY720
treatment as a consequence of inhibited microglia activation. In
addition to activated microglia other glial cell types (e.g.
astrocytes) are known to release pro-inflammatory cytokines
under pathological conditions. Given that astrocytes express differ-
ent S1P receptors these cells might have also contributed to the
observed decline in cerebral cytokine levels following FTY720
treatment. Astrocytes react with a biphasic response to hyperoxia,
i.e. GFAP and glutamate uptake transporter expression is
down-regulated immediately after hyperoxia whereas GFAP
significantly increases on P12 (Schmitz et al., 2011). These data
suggest that astrocytes rather protect oligodendrocyte precursor
cells from glutamate-induced toxicity after hyperoxia than
contribute to acute induction of pro-inflammatory cytokines
(e.g. IL-1b and TNFa). Nevertheless, direct effects of FTY720 on
astrocytes cannot be excluded. This is supported by the elementary
work of Choi et al. showing that treatment efficacy of FTY720 in
experimental autoimmune encephalomyelitis (EAE) is dependent
on S1P1 expression on astrocytes (Choi et al., 2011). However,
EAE involves autoimmune inflammation which is different from
local inflammatory reactions after hyperoxia in the neonatal brain.
Molecular mechanisms of myelin maturation disturbances differ
with respect to its cause and to developmental factors. Moreover,
local inflammatory responses (i.e. cytokine production) were
assessed in Nestin-S1P1 knockout mice (Choi et al., 2011). Taken
into account that Nestin is also supposed to be expressed by
oligodendrocyte progenitor cells (Walker et al., 2010) and is a
marker for neural precursor cells which can differentiate into
neuronal and glial CNS cell types (Wiese et al., 2004), direct
effects of astrocyte specific S1P1 modulation in neonatal
brain injury and hyperoxia-induced inflammation remain to be
clarified.
Perinatal exposure to IL-1b alters the developmental program of
the white matter resulting in magnet resonance imaging
abnormalities and cognitive deficits (Favrais et al., 2011). Therefore
FTY720 might improve memory function and restoration of
long-term structural white matter development by reduction of
microglia activation and cytokine production. Furthermore,
FTY720 ameliorates hyperoxia-induced oxidative stress levels.
Nitric oxide production is a key target mechanism of FTY720’s ben-
eficial effects in experimental autoimmune encephalomyelitis
(Colombo et al., 2014). Since oxidative stress is a major hallmark
of hyperoxia-mediated brain injury involving lipid peroxidation,
glutathione oxidation and reduction (Felderhoff-Mueser et al.,
2004; Sifringer et al., 2010), the anti-oxidative capacity of
FTY720 demonstrated in the present study might act in concert
with reduced brain inflammation to create a beneficial microenvi-
ronment for increased survival, maturation and differentiation of
immature oligodendrocytes.
Whereas neuroprotective effects of FTY720 were mainly
attributed to immunomodulatory and neurotrophic effects,
(re)-myelination has rarely been addressed in relevant neurode-
generative experimental models. The present study emphasises
that protection of oligodendrocyte development and restoration
of white matter structures after neonatal hyperoxia might be an
important mode of action of FTY720. Analysing specific brain
regions commonly affected in preterm infants (Volpe, 2009), we
demonstrate that FTY720 treatment decreases oligodendrocyte
degeneration which is accompanied by an improved maturation
of Olig2 positive cells at P7 culminating in increased myelination
at P11. Noteworthy, these acute protective effects onoligodendrocytes were not associated with general tissue atrophy
(data not shown) or neuronal degeneration in white matter and
hippocampus supporting the hypothesis that long term
hyperoxia-induced cognitive deficits which were improved by
FTY720 may be rather attributed to specific alterations in
oligodendrocyte cellularity and structures of the white matter than
to overall tissue loss or hippocampal neurodegeneration.
Studies focusing on the in vivo evaluation of FTY720 on myeli-
nation reveal contradicting results. In an adult model of
cuprizone-induced demyelination FTY720 treatment decreased
cell degeneration, astro- and microgliosis and normalised levels
of oligodendrocyte maturation and myelination, probably due to
reduced inflammatory cytokine expression, such as IL-1b (Kim
et al., 2011). However, recent findings in the same model did not
confirm these striking effects (Slowik et al., 2015). It must be fur-
ther taken into account that oligodendrogenesis and myelination
differ between adult and postnatal brains, with a specific growth
factor and gene expression pattern and also different proliferation
and differentiation capacities (Greenwood and Butt, 2003; Kang
et al., 2010). In accordance FTY720 improves brain development
in a neonatal model of endotoxin-sensitised hypoxia–ischemia
(Yang et al., 2014). Whereas this study identifies immunomodula-
tion and protection of degenerating neurons as target mechanisms,
direct effects on oligodendrocyte development and myelination
have been recently addressed in human oligodendrocyte progeni-
tors under normoxic cell culture conditions (Cui et al., 2014). We
did not observe any modulation of myelination by pFTY720 under
normoxic conditions which is most probably due to species differ-
ences and another treatment paradigm. As such, we performed
analysis immediately after a single treatment for 24 h whereas
Cui et al. used a repetitive (daily) treatment regime to observe
increased myelination after 4 weeks. Nevertheless, this study is a
fundamental report on the molecular targets of pFTY720 demon-
strating that a single dose of pFTY720 results in rapid Erk1/2 acti-
vation which is reversed to control levels at 4 h whereas repeated
treatment blocks Erk1/2 activation (Cui et al., 2014). We did not
observe significant alterations of Erk1/2 activation by pFTY720 in
our treatment regime (data not shown) which might be explained
by the chosen late time point of analysis (24 h) after a single treat-
ment. A report from a spheroid cell culture system suggested
effects of FTY720 on remyelination via modulation of microglial
responses (Jackson et al., 2011). Therefore we wondered whether
improved myelination might be a consequence of a preserved
microenvironment involving reduction of inflammation and
oxidative stress or whether oligodendrocytes are directly
targeted. By the use of in vitro cultures we show that a single
treatment with activated FTY720 exerts cytoprotective effects on
pre-oligodendrocytes and increases oligodendrocyte maturation
after hyperoxia. Similar results have been obtained in studies
investigating serum withdrawal or growth factor deprivation even
though culture conditions and the duration of pFTY720 treatment
differed (Coelho et al., 2007; Jung et al., 2007). Further evaluation
of S1P1 expression demonstrated that the hyperoxia-induced
increase in S1P1 expression was downregulated by pFTY720.
Since differences were evident on protein but not on mRNA
level pFTY720s’ protective effect might be mediated
through S1P1 modulation on pre-oligodendrocytes most likely
through receptor internalization as previously described for
other cell types (Mullershausen et al., 2009). Interestingly,
selective pharmacological S1P1 blockade diminished pFTY720s’
protection suggesting direct interactions of FTY720 with the S1P1
resulting in decreased hyperoxia-induced pre-oligodendrocyte
degeneration.
Except from blood lymphocyte counts we did not observe sig-
nificant in vivo baseline effects of FTY720 (i.e. NO vs. NO
+ FTY720) and neither the percentage of apoptotic cells nor MBP
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up to 1000 nM of pFTY720 in the normoxia control group in vitro.
However, potential undesired effects cannot be excluded since
continuous treatment regimes and/or higher doses might result
in harmful effects with regard to differentiation and cell survival
(Jung et al., 2007; Kohne et al., 2012). As such, we observed cell loss
after prolonged treatment with higher doses (data not shown).
Potential toxic effects elicited by other pharmacological regimes
need to be further investigated which is beyond of the scope of
the current study.
Since a large number of very immature infants suffer from
white matter injury associated with cognitive and behavioural def-
icits in later life there is an urgent need for treatment strategies
preventing tissue loss and/or promoting repair of white matter
injury. FTY720 is already in clinical use in adult multiple sclerosis
and studies in childhood multiple sclerosis are currently under
way. We show that it confers white matter protection and provides
the features of a promising neuroprotectant also for developmental
brain injury. When considering an immunomodulatory agent as a
neuroprotectant for the developing organism one has to take the
immaturity of the immune system of preterm infants into account.
There are strong distinctions between the newborn infants’ and the
adults’ immune system with relatively few T cells in the preterm
organism. It has recently been shown that preterm infants physio-
logically display a strong tendency towards TH2 responses upon a
viral or bacterial stimulus and a markedly reduced TH1 response
including production of TH17 cytokines (Gibbons et al., 2014),
which might be modulated by FTY720. Although a single applica-
tion of FTY720 conferred neuroprotection without detectable side
effects as shown by regular weight gain of animals we observed
a hyperoxia-independent acute reduction of circulating lympho-
cyte counts after FTY720 treatment. However, diffusible inflamma-
tory mediators were not modulated and thus may not have
interfered with brain pathology in this specific setting. This is fur-
ther supported by the fact that lymphocyte counts in the brain
were not modulated by FTY720 and hyperoxia. Nevertheless,
peripheral immune responses in a clinical setting cannot be
excluded and should be carefully considered in future longitudinal
studies.
Taken together, we show the pleiotropic action of FTY720 on
different neural cell types by reduction of inflammation and oxida-
tive stress and a direct action on oligodendrocyte precursor cells
leads to improved functional outcome following neonatal hyperox-
ia. Our findings add important knowledge to FTY720’s mode of
action in the developing CNS in addition to its established effects
on the peripheral immune system and particularly emphasises
the need for further pre-clinical research also in other models of
perinatal brain injury.Funding sources
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